Page 71 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Designing miRNA ONTs for cardiometabolic pandemics

in obese mice. Mol Metab. 2022;63:101533. doi: 10.3390/ijms24066012
doi: 10.1016/j.molmet.2022.101533 142. Pirillo A, Catapano AL. Inclisiran: How Widely and When
Should We Use It? Curr Atheroscler Rep. 2022;24(10):803-811.
135. Newsome PN, Ambery P. Incretins (GLP-1 receptor
agonists and dual/triple agonists) and the liver. J Hepatol. doi: 10.1007/s11883-022-01056-0
2023;79(6):1557-1565.
143. Zhang Y, Chen H, Hong L, et al. Inclisiran: A new generation
doi: 10.1016/j.jhep.2023.07.033 of lipid-lowering siRNA therapeutic. Front Pharmacol.
2023;14:1260921.
136. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-
receptor agonist retatrutide for obesity - A phase 2 trial. doi: 10.3389/fphar.2023.1260921
N Engl J Med. 2023;389:514-526.
144. Desai NR, Campbell C, Electricwala B, et al. Cost
doi: 10.1056/NEJMoa2301972 effectiveness of inclisiran in atherosclerotic cardiovascular
patients with elevated low-density lipoprotein cholesterol
137. Harrison SA, Taub R, Neff GW, et al. Resmetirom for
nonalcoholic fatty liver disease: A randomized, double- despite statin use: A threshold analysis. Am J Cardiovasc
blind, placebo-controlled phase 3 trial. Nat Med. Drugs. 2022;22(5):545-556.
2023;29(11):2919-2928. doi: 10.1007/s40256-022-00534-9
doi: 10.1038/s41591-023-02603-1 145. Mody R, Valentine WJ, Hoog M, Sharland H, Belger M.
Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-
138. Karim G, Bansal MB. Resmetirom: An orally administered,
smallmolecule, liver-directed, β-selective THR agonist for the term cost-effectiveness analysis in patients with type 2
treatment of non-alcoholic fatty liver disease and non-alcoholic diabetes in the United States. J Manag Care Spec Pharm.
Steatohepatitis. touchREV Endocrinol. 2023;19(1):60-70. 2024;30(2):153-162.
doi: 10.18553/jmcp.2024.30.2.153
doi: 10.17925/EE.2023.19.1.60
146. Kim N, Wang J, Burudpakdee C, et al. Cost-effectiveness
139. Harrison SA, Bedossa P, Guy CD, et al. A phase 3,
randomized, controlled trial of resmetirom in NASH with analysis of semaglutide 2.4 mg for the treatment of adult
liver fibrosis. N Engl J Med. 2024;390(6):497-509. patients with overweight and obesity in the United States.
J Manag Care Spec Pharm. 2022;28(7):740-752.
doi: 10.1056/NEJMoa2309000
doi: 10.18553/jmcp.2022.28.7.740
140. Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M. Novel
anti-obesity therapies and their different effects and safety 147. Damase TR, Sukhovershin R, Boada C, Taraballi F,
profiles: A critical overview. Diabetes Metab Syndr Obes. Pettigrew RI, Cooke JP. The limitless future of RNA
2023;16:1767-1774. therapeutics. Front Bioeng Biotechnol. 2021;9:628137.
doi: 10.3389/fbioe.2021.628137
doi: 10.2147/DMSO.S392684
148. Zhang C, Zhang B. RNA therapeutics: Updates and future
141. Rakocevic J, Dobric M, Vucic R, et al. Small interfering
ribonucleic acid as lipid-lowering therapy: Inclisiran in potential. Sci China Life Sci. 2023;66(1):12-30.
focus. Int J Mol Sci. 2023;24(6):6012. doi: 10.1007/s11427-022-2171-2

Volume 7 Issue 3 (2024) 18 doi: 10.36922/itps.3025